Steven Gannon is Director at Xenon Pharmaceuticals Inc. (XENE). They have made 8 open-market trades across 2 companies since 2017, most recently 2026-08-11.
CIK 0001643085
5 open-market purchases totalling $319K since 2017, against 3 sales. Across 5 scored buys the stock is down 17.4% at ninety days, and 19.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| FUSN | 56,400 | $1.2M |
| XENE | 1,870 | $63K |
| Total | $1.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 100% | 0% |
| Avg Move | +12.2% | +15.3% | -17.4% |
| Alpha | +12.0% | +16.3% | -19.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | SELL | 2026-08-11 | 2026-08-13 | $64.06 | $641K | -4.3% | -7.8% | — |
| XENE | SELL | 2025-06-05 | 2025-06-06 | $30.48 | $91 | -0.3% | -0.5% | +20.8% |
| XENE | SELL | 2024-03-07 | 2024-03-08 | $46.28 | $602K | -4.2% | -6.7% | -17.2% |
| FUSN | BUY | 2022-08-11 | 2022-08-11 | $2.03 | $180K | -0.5% | +28.6% | -4.5% |
| FUSN | BUY | 2021-08-23 | 2021-08-23 | $7.99 | $23K | +11.7% | +8.7% | -26.5% |
| FUSN | BUY | 2021-08-18 | 2021-08-20 | $8.05 | $26K | +11.7% | +5.3% | -24.2% |
| FUSN | BUY | 2021-08-16 | 2021-08-17 | $8.10 | $49K | +13.1% | +9.7% | -21.1% |
| XENE | BUY | 2017-08-11 | 2017-08-14 | $2.82 | $42K | +25.0% | +24.0% | -10.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.